Tempest Expands In Vivo CAR-T Portfolio with Exclusive Option to License Senlang’s CD7-Targeted Platform — Tempest Therapeutics, Inc.

Event summary

Tempest secures exclusive option to license Senlang’s CD7-targeted lentiviral in vivo CAR-T platform, including a Phase 1 BCMA/GPRC5D dual-targeting candidate for relapsed/refractory multiple myeloma.
Lead program demonstrates in vivo CAR-T generation and expansion with no Grade 3+ cytokine release syndrome or neurotoxicity observed as of August 25, 2026.
Option complements Tempest’s existing CD7-targeted lipid nanoparticle platform, set to enter clinic later in 2026.
Portfolio includes additional candidates for hematologic malignancies and autoimmune diseases.

The big picture

Tempest’s move to secure an exclusive option for Senlang’s CD7-targeted platform underscores the growing strategic importance of multi-platform approaches in the in vivo CAR-T space. The deal positions Tempest to compete more effectively in both oncology and autoimmune indications, where immune reset therapies are gaining traction. The Phase 1 data for the BCMA/GPRC5D candidate suggests early clinical validation, which could accelerate Tempest’s pipeline expansion if the option is exercised.

What we're watching

Clinical Validation: Whether the Phase 1 dose escalation results will support continued development of Senlang’s BCMA/GPRC5D dual-targeting candidate.
Platform Synergy: How Tempest integrates the lentiviral platform with its existing lipid nanoparticle technology to expand its immune reset portfolio.
Market Differentiation: The pace at which Tempest can establish its dual-platform approach as a competitive advantage in the in vivo CAR-T space.